JP7466663B2 - 複数の機能を有するピラジン化合物とその製造方法及び使用 - Google Patents
複数の機能を有するピラジン化合物とその製造方法及び使用 Download PDFInfo
- Publication number
- JP7466663B2 JP7466663B2 JP2022548925A JP2022548925A JP7466663B2 JP 7466663 B2 JP7466663 B2 JP 7466663B2 JP 2022548925 A JP2022548925 A JP 2022548925A JP 2022548925 A JP2022548925 A JP 2022548925A JP 7466663 B2 JP7466663 B2 JP 7466663B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- acid
- olb
- mice
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical class C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title description 6
- 150000003839 salts Chemical class 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 22
- -1 pyrazine compound Chemical class 0.000 claims description 18
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 12
- 150000003216 pyrazines Chemical class 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000003414 extremity Anatomy 0.000 description 9
- 238000001543 one-way ANOVA Methods 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 230000004770 neurodegeneration Effects 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 206010027175 memory impairment Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 206010006100 Bradykinesia Diseases 0.000 description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 208000006083 Hypokinesia Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 208000033679 diabetic kidney disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 229960004181 riluzole Drugs 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002083 C09CA01 - Losartan Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 3
- 229960004773 losartan Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- HTMGQIXFZMZZKD-UHFFFAOYSA-N 5,6,7,8-tetrahydroisoquinoline Chemical compound N1=CC=C2CCCCC2=C1 HTMGQIXFZMZZKD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- IGWHDMPTQKSDTL-JXOAFFINSA-N TMP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IGWHDMPTQKSDTL-JXOAFFINSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 208000012268 mitochondrial disease Diseases 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- PQBAWAQIRZIWIV-UHFFFAOYSA-N N-methylpyridinium Chemical class C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101710151717 Stress-related protein Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
Description
I
式において、Xは、O、S、SeまたはNR6から選択され、R1、R2、R3、R4、R5およびR6はそれぞれ独立してH、重水素、ハロゲン、ヒドロキシル基、アミノ基、カルボキシル基、アミド基、エステル基、置換または非置換アルキル基、置換または非置換アルケニル基、置換または非置換アルキニル基、置換または非置換シクロアルキル基、置換または非置換複素環式基、置換または非置換アルコキシ基、置換または非置換アルキル基カルボキシル基、置換または非置換アルキル基エステル基、-置換または非置換アルキル基-OH、置換または非置換アルコキシ基、アルキルアミノ基、-置換または非置換アルキル基-NH2、置換または非置換アリール基、置換または非置換複素環式アリール基、置換または非置換カーボネート基、カルバメート、-置換または非置換アルキル基-アシル基アミノ基、-置換または非置換アミノ基アルキル基カルボン酸エステル、または上記の重水素化誘導体であり、n=0~6、m=0~5である。
「立体異性体」または「光学異性体」は、化学組成は同じであるが、空間内の原子または基の配置が異なる化合物であり、「非鏡像異性体」と「鏡像異性体」を含む。
化合物OLB-3の合成
リグストラジン(13.6g、100.0mmol)を水(300mL)に溶解し、過マンガン酸カリウム(31.6g、200.0 mmol)を少しずつ加え、混合物を50℃で10時間撹拌した。反応が終了した後、冷却し、塩酸でpHを3に調整し、酢酸エチルで抽出し、無水硫酸ナトリウムで乾燥させ、濾過し、そして濃縮して、生成物TMA(10.3g、62%)を得た。1H NMR(400MHz,CDCl3)δ2.90(s,3H),2.61(s,3H),2.56(s,3H)。MS(ESI)m/z:167.0[M+H]+。
化合物イミダゾール(6.2g、90.5mmol)およびtert-ブチルジメチルシリルクロリド(13.6g、90.5mmol)をN、N-ジメチルホルムアミド(200mL)に溶解し、化合物1a(5.0g、36.2mmol)を少しずつ加え、室温で一晩撹拌した。反応が終了した後、水で希釈し、n-ヘキサンで抽出し、無水硫酸ナトリウムで乾燥し、濾過し、濃縮し、得られた粗生成物の一部(3.7g)をメタノール(40mL)に溶解し、ヨウ素元素(0.4g)を加えて2時間撹拌し、反応が終了した後、チオ硫酸ナトリウムを加えてクエンチし、濃縮し、エーテルで希釈して、水および飽和食塩水で洗浄し、硫酸ナトリウムで乾燥させ、濾過し、濃縮し、シリカゲルカラムクロマトグラフィーにより生成物1b(2.0 g、83%)が得られた。1H NMR(400MHz,DMSO-d6)δ6.92(d,J=8.5Hz,2H),6.69-6.49(m,2H),4.41(t,J=5.2Hz,0H),3.40(td,J=7.1,5.3Hz,2H),2.49(t,J=7.1Hz,2H),0.78(s,9H),0.07(s,6H)。MS(ESI)m/z:253.2[M+H]+。
化合物1b(830mg、3.3mmol)およびクロロギ酸クロロメチル(460mg、3.6mmol)をジクロロメタン(20ml)に溶解し、氷浴条件下でピリジン(0.3mL)を滴下して加え、室温で一晩撹拌した。反応が終了した後、濾過して濾液を回収して濃縮し、シリカゲルカラムクロマトグラフィーにより生成物1c(703mg、62%)を得た。1H NMR(400MHz,CDCl3)δ6.88(d,J=8.4Hz,2H),6.59(d,J=8.4Hz,2H),5.52(s,2H),4.19(t,J=7.2Hz,2H),2.75(t,J=7.2Hz,2H),0.79(s,9H),0.00(s,6H)。MS(ESI)m/z:345.1[M+H]+。
化合物TMA(332 mg、2.0 mmol)および化合物1c(688 mg、2.0 mmol)をN、N-ジメチルホルムアミド(20 mL)に溶解し、65℃で2時間撹拌した。反応が終了した後、冷却し、酢酸エチルを加えて反応系を希釈し、水と飽和食塩水で連続して洗浄し、有機相を無水硫酸ナトリウムで連続的に乾燥させ、濾過し、濃縮し、シリカゲルカラムクロマトグラフィーにより生成物1d(742mg、78%)を得た。1H NMR(400MHz,CDCl3)δ6.88(d,J=8.4Hz,2H),6.67-6.51(m,2H),5.86(s,2H),4.17(t,J=7.2Hz,2H),2.74(t,J=7.2Hz,2H),2.59(s,3H),2.40(s,6H),0.80(s,9H),0.00(s,6H)。MS(ESI)m/z:475.2[M+H]+。
化合物1d(95mg、0.2mmol)をテトラヒドロフラン(10mL)に溶解し、フッ化水素酸溶液(1.0ml、2.0mmol)を加え、1時間還流反応した。反応が終了した後、飽和重炭酸ナトリウム溶液、水および飽和食塩水で順に洗浄し、有機相を無水硫酸ナトリウムで乾燥させ、濾過し、濃縮し、シリカゲルカラムクロマトグラフィーにより生成物OLB-3(60mg、84%)を得た。1H NMR(400MHz,CDCl3)δ7.05(d,J=8.2Hz,2H),6.74(d,J=8.4Hz,2H),6.02(s,2H),4.32(t,J=7.1Hz,2H),2.90(t,J=7.1Hz,2H),2.76(s,3H),2.58(s,3H),2.57(s,3H)。MS(ESI)m/z:361.1[M+H]+。
MTTアッセイによってTMP(リグストラジン)及びその誘導体の神経保護効果を検出評価する。細胞を培養し、対数増殖期の細胞を収集し、細胞懸濁液の濃度を調整し、薬物治療およびOGD4hインキュベーション後にMTT含有培地を追加し、4時間インキュベートし、ウェルから培地を慎重に吸引し、各ウェルに150μlのDMSO(ジメチルスルホキシド)を加え、シェーカーに置いて10分間低速で振とうし、結晶物を十分に溶解させ、酵素結合免疫吸着測定装置のOD(吸光度)値490nmで各ウェルの吸光度を測定し(同時にゼロ調整ウェル(培地、MTT、ジメチルスルホキシド)、コントロールウェル(セル、同じ濃度の薬物溶解媒体、培養液、MTT、ジメチルスルホキシド)を設定した。データは平均値±SEMとして表され、グループあたりn=8.一元配置分散分析と多重比較では、2つのグループ間に差異が示された。a、p<0.001vs.対照グループ、b、p<0.05vs.OGDグループ、c、p<0.001vs.OGDグループである。
SH-SY5Y細胞を再活性化して培養し、対数成長期の細胞を取り、24時間培養後、SH-SY5Y神経芽細胞腫細胞を1μMオールトランスレチノイン酸で処理して分化を誘導した後、6ウェルペトリ皿に接種して24時間培養した。薬0.2μM(L)または1μM(H)および1μg/mLLPSを培地に添加して24時間処理し、上清の培地を吸引し、炎症性因子と酸化ストレス関連タンパク質の変化をELISAキットで測定し、データは平均値±SEMで表され、グループあたりn=8、一元配置分散分析と多重比較により、2つのグループ間に差異が示された。a、p<0.05vs.LPSグループ、b、p<0.01vs.LPSグループ、c、p<0.001vs.LPSグループである。
正常対照グループ(WT)およびモデルマウスには、生理食塩水10ml/kg/d、ロサルタン15mg/kg/d、TMP(リグストラジン)(5.0mg/kg、0.037mmol/kg)、OLB-3(13.32mg/kg、0.037mmol/kg)容量10mL/kg、1日1回、56日間の連続投与後に血中脂質および血糖関連指数を測定し、データは平均値±SEMとして表され、グループあたりn=6、一元配置分散分析と多重比較により、2つのグループ間に差異が示された。a、p<0.05vs.db/dbグループ、c、p<0.001vs.db/dbグループである。
正常対照グループ(WT)およびモデルマウスには、生理食塩水10ml/kg/d、ロサルタン15mg/kg/d、TMP(5.0mg/kg、0.037mmol/kg)、OLB-3(13.32mg/kg、0.037mmol/kg)容量10mL/kg、1日1回、56日間の連続投与後に血中脂質および血糖関連指数を測定し、データは平均値±SEMとして表され、グループあたりn=6、一元配置分散分析と多重比較により、2つのグループ間に差異が示された。a、p<0.05vs.db/dbグループ、c、p<0.001vs.db/dbグループである。
正常対照グループ(WT)およびモデルマウスには、生理食塩水10ml/kg/d、ロサルタン10mg/kg/d、TMP(5.0mg/kg、0.037mmol/kg)、OLB-3(13.32mg/kg、0.037mmol/kg)容量10mL/kg、1日1回、56日間の連続投与後に尿を取り、尿タンパクレベルを測定し、データは平均値±SEMとして表され、グループあたりn=6、一元配置分散分析と多重比較により、2つのグループ間に差異が示された。p<0.01vs.db/dbグループである。
OLB-3が5*FADマウスの記憶障害を大幅に改善した
6か月の5*FADマウスをOLB-3で3か月間処理した後、新しい物体認識及びY迷路行動を測定した。新しい物体認識:訓練段階では、マウスを室内にさらして、2つの同一の物体(A+A)に5分間慣れさせ、テスト段階では、慣れた物体の1つを別の新しい物体に交換し(A+B)、マウスを室内に戻して5分間これらの物体を探測し、ビデオを録画してマウスをリアルタイムで追跡した。探測とは、マウスが物体に面する鼻、鼻で嗅ぐか触れ、鼻から物体までの距離が2cm以下であることを記録することと定義され、判別指数(DI)は、各オブジェクトを探索するために使用され、計算方法は次のとおりである。(新しい物体を探索する時間-古い物体を探索する時間)/(新しい物体を探索する時間+古い物体を探索する時間)*100.Y迷路:動物を片方の腕の末端に置き、10分以内に各腕に入る動物のシーケンスを記録し、新しい物体認識検出(A)分析により、OLB-3治療グループでは、5*FADマウスは新しい物体の探索にかかる時間の比率を大幅に改善したことがわかり、Y迷路テスト検出(B)分析により、OLB-3治療グループは5*FADマウスの新しい腕における時間の比率を有意に増加させることがわかった。5*FADマウスをそれぞれ低用量(低用量:2.63mg/kg、0.007mmol/kg、以下と同じ)および高用量(高用量:13.32mg/kg、0.037mmol/kg、以下と同じ)でOLB-3治療し、データは平均値±SEMとして表され、各グループn=9~10、一元配置分散分析と多重比較から、2つのグループ間に差異が示された。**p<0.01、***p<0.001vs.WT(正常対照)グループ、#p<0.05、##p<0.01vs.5*FADグループである。
モデリングの3週間後、ラットの回転の数を記録し、ラットが回転するように誘導し、静かで広々とした環境でラットの行動変化を観察し、偽手術グループには回転がなく、6-OHDAを注射した各グループ間に有意差はなく、回転数は約180であった。2週間の治療後、生理食塩水治療モデルグループのラップ回転数が増加し、OLB-3、TMP(リグストラジン)および陽性対照薬L-dopaの異なる用量の2週間後の結果:異なる用量のOLB-3と陽性対照レボドパ(25mg/kg)治療後、APOによって誘発された6-OHDAラットの回転数を効果的に減らすことができる。6-OHDAモデルグループと比較して、OLB-3治療ラットの回転数は大幅に減少し、データは平均値±SEMとして表され、各グループn=10、一元配置分散分析と多重比較から、2つのグループ間に差異が示された。*p<0.05、**p<0.01vs.before6-OHDAグループである。
ポールテストは、マウスの四肢の運動協調性、運動遅延、筋力を評価するためによく使用される。長さ約50cm、直径約1cmの木製のロッドを手作り、木製のロッドの摩擦力を増やすためにロッドは医療用ガーゼで包まれている。木製のロッドを水平のテーブルの上に垂直に置き、マウスの頭を下にして、マウスの尾をつかみ、その四肢はロッドの上部をつかみ、マウスの尾を離した後、タイミングを開始して、マウスが外力なしで下に這うようにし、マウスがロッドの上部から下部のプラットフォームに登る時間(統一に後肢が着地することを基準とする)を記録した。投与前にマウスをこの行動について3日間継続的に訓練し、各マウスを3回繰り返し実験し、基準を満たさなかったマウスを除外した。投与開始後、2週間ごとに1回に行動をテストし、テスト結果の最大値は15秒を超えてはならず、15秒を超える値は15秒として記録され、最終的なポールでの移動時間として、マウスの3回のポールでの移動時間の平均値を計算し、ALS(SOD-G93A)miceマウスは、発症後に明らかな動作緩慢を示し、これは、ポールでの移動時間が対照マウスよりも有意に長く、年齢とともに動作緩慢がより深刻になることを示し、異なる用量のOLB-3、TMP、およびリルゾールで治療した後、OLB-3および陽性対照薬であるリルゾール(5mg/kg)がすべてその動作緩慢の症状を有意に改善できることがわかり、データは平均値±SEMとして表され、各グループn=10、一元配置分散分析と多重比較から、2つのグループ間に差異が示された。*p<0.05vs.WT(正常対照)グループ、#p<0.05vs.ALS(SOD-G93A)グループである。
四肢握力テストは、マウスの筋力及びマウスの発病状況を評価するために直接使用される。握力ボードの中央ステージにマウスを軽く置き、マウスの尾部をそっと引っ張って、マウスが握力ボードをつかむようにし、マウスが握力ネットを強くつかんだ後、直ちに水平に後方へ引っ張り、機器が最大握力の値を示したときにデータを記録した。投与開始後、2週間ごとにマウスの握力値をテストし、各マウスについて3回測定を繰り返し、3回の結果の最大値をマウスの最大握力値とした。ALSトランスジェニックマウスが病期に入った後、その四肢握力はWTマウスよりも有意に小さく、異なる用量のOLB-3、TMP、およびリルゾールで治療した後、OLB-3および陽性対照薬であるリルゾール(5mg/kg)がすべてマウスの四肢の握力を効果的に高め、ALSマウスの四肢の握力の低下の悪化を遅らせることができることがわかり、データは平均値±SEMとして表され、グループあたりn=10、一元配置分散分析と多重比較から、2つのグループ間に差異が示された。**p<0.01、***p<0.001vs.WT(正常対照)グループ、#p<0.05、##p<0.01vs.ALS(SOD-G93A)グループである。
Claims (3)
- ピラジン化合物、立体異性体、互変異性体、およびそれらの薬学的に許容される塩を以下に示すことを特徴とするピラジン化合物、立体異性体、互変異性体、およびそれらの薬学的に許容される塩。
- 化合物の製造方法であって、製造プロセスを以下に示すことを特徴とする化合物の製造方法。
- 化合物であって、以下の構造式を有することを特徴とする化合物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010759395.9 | 2020-07-31 | ||
CN202010759391.0A CN111840293B (zh) | 2020-07-31 | 2020-07-31 | 多种功效的吡嗪类化合物在制备药物中的应用 |
CN202010759391.0 | 2020-07-31 | ||
CN202010759395.9A CN111808032B (zh) | 2020-07-31 | 2020-07-31 | 多种功效的吡嗪类化合物及其制备方法 |
PCT/CN2021/109563 WO2022022677A1 (zh) | 2020-07-31 | 2021-07-30 | 多种功效的吡嗪类化合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023514235A JP2023514235A (ja) | 2023-04-05 |
JP7466663B2 true JP7466663B2 (ja) | 2024-04-12 |
Family
ID=80037670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022548925A Active JP7466663B2 (ja) | 2020-07-31 | 2021-07-30 | 複数の機能を有するピラジン化合物とその製造方法及び使用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230391732A1 (ja) |
JP (1) | JP7466663B2 (ja) |
CA (1) | CA3177962A1 (ja) |
WO (1) | WO2022022677A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005520791A (ja) | 2001-11-08 | 2005-07-14 | イーラン ファーマスーティカルズ、インコーポレイテッド | N,n’−置換−1,3−ジアミノ−2−ヒドロキシプロパン誘導体 |
CN101362725A (zh) | 2008-10-06 | 2009-02-11 | 山东大学 | 川芎嗪胍类衍生物的制备方法及其应用 |
WO2012103813A1 (en) | 2011-02-01 | 2012-08-09 | Jinan University | Danshensu and chuanxiongqin derivatives, process for preparation, and use thereof |
CN105294666A (zh) | 2014-06-19 | 2016-02-03 | 常州喜鹊医药有限公司 | 一种丹参素衍生物及其制备方法和医药应用 |
CN107118166A (zh) | 2017-04-21 | 2017-09-01 | 潍坊医学院 | 一种川芎嗪酰腙类衍生物、制备方法及其应用 |
CN108456178A (zh) | 2017-02-20 | 2018-08-28 | 雷鹏程 | 具有神经保护活性的川芎嗪取代对羟基苯甲醇类似物衍生物(lqc-f)及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA85994C2 (en) * | 2001-11-08 | 2009-03-25 | Элан Фармасьютикалз, Инк. | N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives |
CN102212008B (zh) * | 2010-04-09 | 2014-07-02 | 暨南大学 | 丹参素川芎嗪衍生物及其制备方法和应用 |
CN111808032B (zh) * | 2020-07-31 | 2022-04-12 | 深圳市橄榄生物医药科技有限公司 | 多种功效的吡嗪类化合物及其制备方法 |
CN111840293B (zh) * | 2020-07-31 | 2022-01-18 | 深圳市橄榄生物医药科技有限公司 | 多种功效的吡嗪类化合物在制备药物中的应用 |
-
2021
- 2021-07-30 US US18/018,885 patent/US20230391732A1/en active Pending
- 2021-07-30 CA CA3177962A patent/CA3177962A1/en active Pending
- 2021-07-30 WO PCT/CN2021/109563 patent/WO2022022677A1/zh active Application Filing
- 2021-07-30 JP JP2022548925A patent/JP7466663B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005520791A (ja) | 2001-11-08 | 2005-07-14 | イーラン ファーマスーティカルズ、インコーポレイテッド | N,n’−置換−1,3−ジアミノ−2−ヒドロキシプロパン誘導体 |
CN101362725A (zh) | 2008-10-06 | 2009-02-11 | 山东大学 | 川芎嗪胍类衍生物的制备方法及其应用 |
WO2012103813A1 (en) | 2011-02-01 | 2012-08-09 | Jinan University | Danshensu and chuanxiongqin derivatives, process for preparation, and use thereof |
CN105294666A (zh) | 2014-06-19 | 2016-02-03 | 常州喜鹊医药有限公司 | 一种丹参素衍生物及其制备方法和医药应用 |
CN108456178A (zh) | 2017-02-20 | 2018-08-28 | 雷鹏程 | 具有神经保护活性的川芎嗪取代对羟基苯甲醇类似物衍生物(lqc-f)及其应用 |
CN107118166A (zh) | 2017-04-21 | 2017-09-01 | 潍坊医学院 | 一种川芎嗪酰腙类衍生物、制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2022022677A1 (zh) | 2022-02-03 |
JP2023514235A (ja) | 2023-04-05 |
US20230391732A1 (en) | 2023-12-07 |
CA3177962A1 (en) | 2022-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111789844B (zh) | 一种吡嗪类化合物在制备药物中的应用 | |
KR102435676B1 (ko) | 독성 알데히드 관련된 질병 및 치료 | |
AU2021414253B2 (en) | Series of piperidine-substituted benzoic acid compounds, and use thereof | |
JP2023171614A (ja) | アルドース還元酵素阻害剤およびその使用方法 | |
JP2022504697A (ja) | Ssao阻害剤とその使用 | |
CN111840293B (zh) | 多种功效的吡嗪类化合物在制备药物中的应用 | |
CN111793036B (zh) | 一种吡嗪类化合物及其制备方法 | |
IE920449A1 (en) | Imidazopyridine PAF/H1 antagonists | |
EP4166541A1 (en) | Dimethylsulfoximine derivative | |
JP7169592B2 (ja) | Pac1受容体拮抗薬を用いた鎮痛薬 | |
CN114456163A (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
CN111808032B (zh) | 多种功效的吡嗪类化合物及其制备方法 | |
JP7466663B2 (ja) | 複数の機能を有するピラジン化合物とその製造方法及び使用 | |
CN110669017B (zh) | 多取代三唑甲酸酯类衍生物及其用途 | |
CN110724106B (zh) | 取代吡唑甲酸酯类衍生物及其用途 | |
CN109761906B (zh) | 一种取代咪唑甲酸酯类衍生物及其用途 | |
JP7466664B2 (ja) | ピラジン化合物およびその調製方法と使用 | |
DE4210942A1 (de) | 7-Oxo-7H-pyrido[1,2,3-d,e][1,4]benzoxacin-6-carbonsäuren und -ester | |
AU2022341311A1 (en) | Ahr agonists | |
CN113773293A (zh) | 一种白杨素衍生物及其制备方法 | |
JP3471778B2 (ja) | 三環性縮合複素環化合物、その製造方法および用途 | |
JP7504234B2 (ja) | ジメチルスルホキシミン誘導体 | |
WO2023001268A1 (zh) | 一种白杨素衍生物及其制备方法和应用 | |
JPS604170A (ja) | キノロン誘導体 | |
WO2024046277A1 (zh) | 一系列含氮桥杂环化合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220810 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220810 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230829 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231117 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7421 Effective date: 20231117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240313 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240402 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7466663 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |